CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Bristol Myers Squibb
Main (gene editing) focus: Next-generation cellular therapies
Company stage: Commercial
Diseases (gene editing): Acute myeloid leukaemia (AML), multiple myeloma (MM), other haematological and solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:BMY)
Location: New York City, New York, USA
Website: https://www.bms.com/
Pipeline: https://www.bms.com/researchers-and-partners/in-the-pipeline.html
Gene editing partnerships: Century Therapeutics
Bristol Myers Squibb (BMS) is a big pharma company developing drugs within many different disease areas. The company is engaged in the gene-editing space through its collaboration with Century Therapeutics, which is an early stage company developing gene-edited iPSC-derived cellular therapies. Together, the two companies will develop programmes with the intent to treat acute myeloid leukaemia and multiple myeloma.
